Increased circulating IL-2Ra (CD25) predicts poor outcome in both indolent and aggressive forms of mastocytosis: a comprehensive cytokine-phenotype study Leukemia (2013) 27, 1430-1433; doi:10.1038/leu.2013.11
The clinical phenotype of systemic mastocytosis (SM) is highly variable; establishing prognosis in individual patients is not trivial. The classification of adult SM patients per the 2008 World Health Organization (WHO) system 1 has been validated for its prognostic utility. 2 In addition to WHO SM subtype, an independent association between inferior survival and advanced age, weight loss, anemia, thrombocytopenia, hypoalbuminemia and excess bone marrow (BM) blasts has been demonstrated. 2 Aside from advanced age, however, the aforementioned parameters are typically applicable only to patients with advanced SM subtypes (that is aggressive SM (ASM), SM associated with clonal non-mast cell lineage disease (SM-AHNMD) or mast cell leukemia). In contrast, patients with indolent SM (ISM) have a normal life expectancy; their risk of transformation to acute leukemia or ASM has been estimated to be 1% and 3%, respectively. 3, 4 Predictors of disease progression include advanced age, increased serum b2-microglobulin level and multilineage presence of KITD816V. Recent studies in primary myelofibrosis, 5 myelodysplastic syndrome 6 and diffuse large B-cell lymphoma 7 have demonstrated an abnormal circulating cytokine milieu reflecting the host response to clonal proliferation. In these studies, specific cytokines were found to be prognostically relevant, independent of known disease-specific prognostic factors. Here, we conducted a comprehensive analysis of circulating cytokines/chemokines with clinicopathologic and clinical outcome correlations in a cohort of SM patients.
Accepted article preview online 15 January 2013; advance online publication, 1 February 2013 Letters to the Editor The current study was approved by our institutional review board. All patients provided written informed consent for plasma sample collection as well as participation in the research study. Inclusion to the current study required availability of archived plasma, BM biopsy and cytogenetic information at the time of first referral. The diagnosis of SM and its subclassification was according to the WHO criteria. 1, 8 Concentrations of 30 plasma cytokines were analyzed in duplicates using Multiplex Bead-based Luminex Technology (Invitrogen, Carlsbad, CA, USA), as previously described. 5 Molecular analysis for KITD816V was performed using a sensitive (0.01%) allele-specific PCR assay as previously described. 2 Table 1 .
We initially compared plasma cytokine levels in SM patients with normal controls (n ¼ 35). Significant differences (Po0.05) were noted for 23 of 30 cytokines evaluated (Supplementary Table 1 ), all of which were increased in SM patients except for interleukin (IL)-17, granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor and regulated on activation normally T-cell expressed and secreted. When comparing cytokine levels between the three SM subgroups, only IL-8 was significantly different (P ¼ 0.0002), with higher levels in SM-AHNMD as compared with ISM or ASM (Supplementary Table 2 ). When the analysis was simplified to compare cytokine levels between ISM and advanced SM patients (as ASM and SM-AHNMD both represent advanced disease), significant differences were noted for IL-8 (P ¼ 0.005) and IL-6 (P ¼ 0.03); higher levels of both cytokines were recorded in advanced SM patients.
We next analyzed for clinical correlations of circulating cytokines: presence of constitutional symptoms and/or weight loss was associated with a broad increase in circulating cytokine levels, namely plasma IL-2 receptor alpha (sIL-2Ra), IL-4, IL-5, IL-6, IL-10, IL-13, IL-15 and interferon (IFN)-g-inducible protein 10 (IP-10) (all Po0.05). Increased levels of many of the aforementioned cytokines (sIL-2Ra, IL-4, IL-5, IL-6, IL-8, IL-10 and IL-13) were also associated with hepatosplenomegaly (all Po0.05). Age 465 years was correlated with increased sIL-2Ra levels (P ¼ 0.0003), and hemoglobin o10 g/dl was associated with increased levels of IL-8 (P ¼ 0.007) and IL-6 (P ¼ 0.04). Presence of absolute eosinophilia (circulating eosinophil count 41.5 Â 10 9 /L) was associated with increased levels of IL-5 (P ¼ 0.02) and eotaxin (P ¼ 0.04), which represent key trophic and chemoattractant cytokines for eosinophils. BM mast cell (MC) burden correlated with sIL-2Ra (r 2 ¼ 0.30; Po0.0001), IL-12 (r 2 ¼ 0.20; P ¼ 0.001), and monokine induced by IFN-g (MIG) (r 2 ¼ 0.16; P ¼ 0.004) levels, and serum tryptase with sIL-2Ra (r 2 ¼ 0.14; P ¼ 0.01) and MIG (r 2 ¼ 0.11; P ¼ 0.02) levels.
When the analysis was limited to ISM patients, presence of high MC burden ('B-findings') including hepatosplenomegaly (P ¼ 0.005), BM MC 430% (P ¼ 0.004) and serum tryptase levels 4200 ng/ml (P ¼ 0.005) were associated with increased sIL-2Ra levels. None of the surveyed cytokines was associated with history of anaphylaxis; however, presence of MC mediator symptoms correlated with decreased levels of IL-8 and hepatocyte growth factor (Po0.05). BM MC burden showed strong correlation with sIL-2Ra levels (r 2 ¼ 0.61; Po0.0001) and serum tryptase with sIL-2Ra (r 2 ¼ 0.34; P ¼ 0.004) and MIG (r 2 ¼ 0.42; P ¼ 0.001) levels. After a median follow-up of 28 months (range 0-116), 20 (43%) deaths and 3 (13%) and 1 (2%) transformations to ASM and mast cell leukemia, respectively, were recorded for the overall cohort. In univariate analysis, increased sIL-2Ra levels were associated with inferior overall survival (P ¼ 0.005); this prognostic Of the 15 patients with SM-AHNMD, the breakdown was as follows: chronic myelomonocytic leukemia ¼ 5, primary myelofibrosis ¼ 3, myelodysplastic syndrome (MDS) ¼ 2, acute myeloid leukemia ¼ 1, essential thrombocythemia ¼ 1, polycythemia vera ¼ 1, myeloproliferative neoplasm/myelodysplastic syndrome-not otherwise specified (MPN/MDS-NOS) ¼ 1 and myeloproliferative neoplasm-not otherwise specified MPN-NOS ¼ 1.
Letters to the Editor significance was maintained in multivariate analysis after adjusting for other known prognostic variables individually (that is WHO SM subtype, hemoglobin o10 g/dl, thrombocytopenia, weight loss or hypoalbuminemia) (all Po0.05) and was borderline significant with age 465 years (P ¼ 0.056) (Supplementary Table 3) . Similarly, increased sIL-2Ra levels (defined as 475th percentile; i.e. 41902 pg/ml) were associated with inferior survival (hazard ratio 4.7; P ¼ 0.001), and was also independent of the other known prognostic variables (Supplementary Table 3 ). Furthermore, sIL-2Ra levels 475th percentile effectively stratified patients in the overall cohort into two well-delineated risk groups for overall survival (median survival 109 vs 26 months; P ¼ 0.0004) (Figure 1a ). This sIL-2Ra threshold was also able to effectively risk stratify patients within ISM (median survival not reached vs 38 months) and advanced SM (median survival 31 vs 5 months) categories (Po0.0001) (Figure 1b) .
Novel aspects of the current study include a detailed description of the dysregulated cytokine milieu in SM, complemented by the identification of specific cytokine-phenotypic associations and identification of a significant prognostic role for sIL-2Ra in this disease. IL-8 and IL-6 stand out as being strongly associated with advanced SM; this accounts for their significant association with constitutional symptoms, weight loss, organomegaly and anemia. The observations regarding IL-8 were reproducible even when the analysis was restricted to ISM patients, and similar observations have also been reported in primary myelofibrosis; 5 suggesting that levels of this pro-inflammatory cytokine may mirror the strength of the underlying clonal proliferative process.
sIL-2Ra was highly relevant, both as a surrogate measure of the underlying systemic MC burden, and as a powerful prognostic marker for overall survival. Although sIL-2Ra levels have been shown to be correlated with bone MC burden, their impact on survival has not been previously studied in mastocytosis patients. 9 IL-2Ra (CD25) is aberrantly expressed on neoplastic MC in virtually all cases of SM, 10 and MC CD25 expression counts as one of four minor criteria towards the diagnosis of SM per the WHO system. 1 The circulating or soluble form of IL-2Ra is a truncated molecule generated by extracellular proteolytic cleavage of membrane-IL-2Ra; increased sIL-2Ra a levels have been documented in various hematological and solid tumors and inflammatory diseases, where they correlate with poor-risk disease features. sIL-2Ra levels were strongly correlated with BM MC burden; the coefficient of determination (adjusted r 2 ) using linear regression analysis was 0.61 in ISM, meaning that 61% of the variation in sIL-2Ra levels could be predicted by variation in BM MC burden. It is not surprising that the regression model fit the data less ideally in advanced SM (adjusted r 2 ¼ 0.30); two-thirds of cases in this category were comprised of SM-AHNMD where there is inherently greater uncertainty regarding BM MC quantification, given the underlying diffuse infiltration by non-SM hematologic neoplasm. 12 The correlation of serum tryptase with sIL-2Ra levels further supports the contention that sIL-2Ra levels serve as a surrogate measure of the systemic MC burden.
Increased sIL-2Ra levels provided important prognostic information in terms of overall survival in advanced and ISM. The current data set was well suited for the survival analysis, given the relatively mature follow-up with nearly half the patients followed until death. Five of 23 (22%) ISM patients (three of whom had smoldering SM) died during the follow-up period; the higher than expected mortality rate in this patient subgroup likely reflects a referral bias towards higher-risk patients seen at our institution. The pathogenic mechanisms underlying the association of increased sIL-2Ra levels with inferior survival are likely complex but can be speculated to reflect the aforementioned higher systemic MC burden (however, notably, this association was independent of conventional measures of organopathy due to MC infiltration), but also sIL-2Ra-mediated immunosuppression. 13 Although the prognostic value of increased sIL-2Ra levels was independent of several known prognostic variables in mastocytosis, the current analysis did not consider its interaction with multilineage KITD816V involvement or increased b2-microglobulin levels in the multivariate model. Figure 1 . Overall survival Kaplan-Meier survival curves of SM patients stratified by sIL-2Ra level above or below the 75th percentile (1902 pg/ml). Panel a shows that SM patients with sIL-2Ra level 475th percentile had a significantly inferior survival (n ¼ 12; median survival ¼ 25.6 months) as compared with those with sIL-2Ra level p75th percentile (n ¼ 34; median survival ¼ 109.2 months) (log rank P ¼ 0.0004). This association with inferior overall survival was sustained on multivariate analysis that considered other standard prognostic variables individually. Panel b shows patients with ISM and ASM stratified by sIL-2Ra levels above or below the 75th percentile. The following subgroups were identified: ISM and sIL-2Ra level p75th percentile (n ¼ 19; median survival ¼ not reached); ISM and sIL-2Ra level 475th percentile (n ¼ 4; median survival ¼ 38.4 months); advanced SM (non-ISM) and sIL-2Ra level p75th percentile (n ¼ 15; median survival ¼ 31.3 months); and advanced SM (non-ISM) and sIL-2Ra level 475th percentile (n ¼ 8; median survival ¼ 4.5 months) (Po0.0001).
